Key PointsPfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.